Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification

The HER3 receptor is implicated in the progression of various cancers as well as in resistance to several currently used drugs, and is hence a potential target for development of new therapies. We have previously generated Affibody molecules that inhibit heregulin-induced signaling of the HER3 pathw...

Descripción completa

Detalles Bibliográficos
Autores principales: Malm, Magdalena, Kronqvist, Nina, Lindberg, Hanna, Gudmundsdotter, Lindvi, Bass, Tarek, Frejd, Fredrik Y., Höidén-Guthenberg, Ingmarie, Varasteh, Zohreh, Orlova, Anna, Tolmachev, Vladimir, Ståhl, Stefan, Löfblom, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651084/
https://www.ncbi.nlm.nih.gov/pubmed/23675426
http://dx.doi.org/10.1371/journal.pone.0062791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651084/
https://www.ncbi.nlm.nih.gov/pubmed/23675426
http://dx.doi.org/10.1371/journal.pone.0062791

Ejemplares similares